Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael McLaughlin

Interventional Pain Medicine Moore, OK Doctor of Osteopathy

NPI 1376779231 CMS profile 1341246

1401 Sw 34Th St Ste 200, Ste 5050, Moore, OK 73160

Open in the dashboard

General payments

$6,877

267 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael McLaughlin of Moore, OK is reported in the CMS Open Payments database as having received $6,877 across 267 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $890 19
2024 General $331 11
2023 General $365 28
2022 General $615 44
2021 General $794 65
2020 General $993 60
2019 General $2,890 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael McLaughlin
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Michael McLaughlin were reported at $890. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Michael McLaughlin Interventional Pain Medicine median Middle half National median
2019 $2,890 $684 $216–$2,079 $163
2020 $993 $382 $122–$1,109 $114
2021 $794 $552 $167–$1,554 $132
2022 $615 $605 $187–$1,924 $149
2023 $365 $671 $195–$1,915 $160
2024 $331 $684 $206–$1,837 $164
2025 $890 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,431 225 payments
  2. Medtronic USA, Inc. $2,322 2 payments
  3. Boston Scientific Corporation $485 4 payments
  4. Medtronic, Inc. $113 3 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $75 5 payments
  6. SPR Therapeutics, Inc $52 3 payments
  7. Pfizer Inc. $50 3 payments
  8. Novo Nordisk Inc $48 3 payments
  9. Amgen Inc. $48 3 payments
  10. Dexcom, Inc. $48 3 payments
  11. Other $206 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,162 265 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,310 1 payment
  3. Travel and Lodging $405 1 payment
Products named General payments · program years 2019–2025
  1. ADAPTIVESTIM $2,310 1 payment
  2. Proclaim Family of SCS IPGs $1,002 56 payments
  3. Proclaim IPG $614 49 payments
  4. PROCLAIM Neuromodulation $578 37 payments
  5. General - Therapies $405 1 payment
  6. PROCLAIM Structural Heart $254 3 payments
  7. Octrode SCS Leads $194 17 payments
  8. ETERNA Neuromodulation $140 10 payments
  9. Prodigy Family of SCS IPGs $137 9 payments
  10. ETERNA Structural Heart $97 6 payments
  11. Other $1,191 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,806

Median for Interventional Pain Management: 1,220

Drug cost

$91,700

Median for Interventional Pain Management: $39,344

Branded share of claims

17%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 97 $28,261
Gabapentin Generic 641 $12,259
Belbuca Buprenorphine Hcl Brand 17 $9,734
Pregabalin Generic 318 $6,869
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 214 $5,458
Celecoxib Generic 141 $4,952
Acetaminophen-Codeine Acetaminophen With Codeine Brand 120 $3,136
Duloxetine Hcl Generic 128 $2,794
Buprenorphine Hcl Generic 67 $2,032
Cyclobenzaprine Hcl Generic 116 $1,959

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$112,550

Of which drugs: $105

Medicare patients

425

Average age 73

Services billed

2,017

253 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 29%
Depression 28%
Chronic kidney disease 24%
COPD 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record